Related Experiment Videos

Do Drugs Work for ΟΑΒ Following Prostate Cancer Surgery

Vasileios Sakalis1, Anastasia Gkotsi1

  • 1Agios Pavlos, General Hospital of Thessaloniki, Urology, Greece.

Current Drug Targets
|July 18, 2020
PubMed

Insights

Over a third of men experience overactive bladder (OAB) after radical prostatectomy, impacting quality of life. Management is challenging, but some medications show promise for improving OAB symptoms.

Area of Science:

  • Urology
  • Oncology
  • Nephrology

Background:

  • Post-radical prostatectomy (post-RP) incontinence is common.
  • A significant portion of men with post-RP incontinence also exhibit overactive bladder (OAB) symptoms.
  • The pathophysiology of OAB post-RP is complex and not fully understood.

Purpose of the Study:

  • To review the incidence, etiology, and management of overactive bladder (OAB) in men following radical prostatectomy (RP).
  • To highlight the challenges in diagnosing and treating post-RP OAB.
  • To summarize current understanding and potential therapeutic approaches for post-RP OAB.

Main Methods:

  • Literature review of studies investigating post-radical prostatectomy incontinence and overactive bladder.
  • Analysis of the multifactorial etiology of OAB in the post-prostatectomy population.
  • Evaluation of diagnostic work-up strategies and treatment options.

Main Results:

  • The incidence of OAB post-RP ranges from 15.2% to 37.8%.
  • Potential causes include bladder decentralization, detrusor underactivity, outlet obstruction, and co-existing stress urinary incontinence (SUI).
  • Anticholinergics and PDE5 inhibitors appear effective in improving OAB parameters.

Conclusions:

  • Overactive bladder (OAB) is a significant issue for men after radical prostatectomy (RP), contributing to incontinence.
  • Personalized diagnosis and treatment are crucial, considering the multifactorial nature of post-RP OAB.
  • Further research is needed for robust management guidelines, though current options like anticholinergics and PDE5 inhibitors show potential.

Related Concept Videos